71590-08-4

Usage

Uses

Used in Ink Production:
METHYL 5-METHOXY-ISOPHTHALATE is used as a key component in the formulation of ballpoint pen inks, providing the necessary color and stability for writing.
Used in Dye Intermediates:
It serves as a dye intermediate, contributing to the production of various dyes used in different industries.
Used in Textile Industry:
METHYL 5-METHOXY-ISOPHTHALATE is used as a raw material for synthesizing polyesters, which are widely used in the textile industry for producing fabrics with desirable properties such as strength, durability, and wrinkle resistance.
Used in Packaging Industry:
In the packaging industry, METHYL 5-METHOXY-ISOPHTHALATE is used in the production of polyester films and containers, known for their lightweight, transparency, and resistance to moisture and chemicals.
Used in Automotive Industry:
It is employed in the synthesis of polyesters for automotive applications, such as in the production of lightweight and durable components, contributing to fuel efficiency and reduced emissions.
Used in Coating and Adhesive Products:
METHYL 5-METHOXY-ISOPHTHALATE is used as a component in the formulation of coating and adhesive products, providing properties like adhesion, flexibility, and resistance to environmental factors.
METHYL 5-METHOXY-ISOPHTHALATE is considered to be relatively low in toxicity and poses minimal environmental risk when handled and disposed of properly, making it a suitable choice for various industrial applications.

InChI:InChI=1/C10H10O5/c1-14-8-4-6(9(11)12)3-7(5-8)10(13)15-2/h3-5H,1-2H3,(H,11,12)

Upstream product

• 20319-44-2 dimethyl 5-methoxyisophthalate 
• 618-83-7 5-Hydroxyisophthalic acid 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 

Downstream Products

• 367519-84-4 3-hydroxymethyl-5-methoxy-benzoic acid methyl ester 
• 1257657-26-3 (S)-7-(allyl-tert-butoxycarbonylamino)-7-[2-(3-methoxy-5-vinylbenzyloxy)-phenylcarbamoyl]-heptanoic acid methyl ester 
• 661458-28-2 methyl 3-cyano-5-methoxybenzoate 
• 453566-61-5 3-cyano-5-methoxybenzoic acid 
• 878741-65-2 3-cyanomethyl-5-methoxy-benzoic acid methyl ester 
• 1257657-35-4 tert-butyl 2-(3-formyl-5-methoxybenzamido)phenylcarbamate 
• 1257657-34-3 N-(2-tert-butoxycarbonylamino-phenyl)-5-methoxy-isophthalamic acid methyl ester 

Relevant academic research and scientific papers

Cobalt(III)-Catalyzed Construction of Benzofurans, Benzofuranones and One-Pot Orthogonal C?H Functionalizations to Access Polysubstituted Benzofurans

Benzofuran and benzofuranone derivatives have been synthesized through exclusive 5-exo-dig intramolecular hydroarylation using the amide-directed, cost-effective, high-valent Cp*CoIII-catalytic system. Challenging one-pot, orthogonal C?H functionalizations using two different electrophiles are also reported to afford polysubstituted benzofurans. Several valuable functional group interconversions along with removal of the amide directing group provide a route to access several diversely functionalized benzofurans. The mechanistic study suggests a reversible cobaltation step is operative here. (Figure presented.).

Birch Reductive Alkylation of Methyl m-(Hydroxymethyl)benzoate Derivatives and the Behavior of o- and p-(Hydroxymethyl)benzoates under Reductive Alkylation Conditions

Birch reductive alkylation of methyl m-(hydroxymethyl)benzoate derivatives, using lithium in ammonia-tetrahydrofuran in the presence of tertbutyl alcohol, can be achieved without significant loss of benzylic oxygen substituents. Similar treatment of o- and p-(hydroxymethyl)benzoate derivatives results largely in loss of benzylic oxygen substituents. The results are rationalized by computations describing electron density patterns in the putative radical anion intermediate involved in these reactions.

Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, composistions thereof and the use for nonsense suppression

Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease

COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS

Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, wherein P Q X1 X2 X3 X4 X5 R R1 R2 R3 R4R5 G M1 M2 M3 m and n are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA receptor

To further develop and evaluate a pharmacophore model previously proposed by Cook and co-workers (Drug Des. Discovery 1995, 12, 193-248) for ligands binding to the benzodiazepine site of the GABAA receptor, 40 new flavone derivatives have been synthesized and their affinities for the benzodiazepine site have been determined. Two new regions of steric repulsive interactions between ligand and receptor have been characterized, and the receptor region in the vicinity of 6- and 3′-substituents has been mapped out. 2′-Hydroxy substitution is shown to give a significant increase in affinity, which is interpreted in terms of a novel hydrogen bond interaction with the previously proposed hydrogen bond-accepting site A2. On the basis of the results of these studies and the refined pharmacophore model, 5′-bromo-2′-hydroxy-6-methylflavone, the highest affinity flavone derivative reported so far (Ki = 0.9 nM), was successfully designed. A comparison of the pharmacophore model with a recently proposed alternative model (Marder; et al. Bioorg. Med. Chem., 2001, 9, 323-335) has been made.

A practical and convenient synthesis of methyl 5-formyl-3-methoxybenzoate

A practical and convenient synthesis of methyl 5-formyl-3-methoxybenzoate starting from 3-hydroxy-5-(methoxycarbonyl)benzoate in 65% overall yield is described. Ethyl 5-formyl-3-methoxybenzoate was also prepared in the similar manner.